The effects of ultrafractionated X-ray therapy in malignant lymphomas.
To improve the therapeutic methods in malignant lymphomas a new irradiation schedule is suggested i.e., ultrafractionated radiotherapy in small daily doses spaced out over a long period of time until the tumor dose of 3,500 R is reached. This treatment was used in 26 patients with malignant lymphomas--most of whom in stages III and IV--as well as in patients with recurrences that no longer responded to chemotherapy. Total remissions were obtained as well as an improvement of survival : 18 of the 16 patients are still in life and 8 of these have already been followed up for more than 5 years. The tumor dose per field did not exceed 2,000 R in the patients under concomitant chemotherapy. Ultrafractionated X-ray was very well tolerated by patients with altered general condition and even by those with recurrences or previous irradiation sequelae.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000532:radiotherapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011879:Radiotherapy Dosage; D014964:X-Ray Therapy
D000970:Antineoplastic Agents